Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Trump Urges for Congress to Pass Right To Try Bill
February 1st 2018After patients have exhausted all therapeutic options in their cancer treatment, oftentimes there is nowhere left for them to turn. Despite a terminal diagnosis, some patients may have more options in their remaining days if one bill is passed – if only it were that easy.
Read More
Exploring Clonal Evolution in Colorectal Cancer
January 27th 2018Patients with microsatellite instability-high (MSI-H) colorectal cancer may undergo a distinct pattern of clonal evolution, which in turn, would impact the use of targeted and immunologic therapies in these patients, according to study results presented at the 2018 Gastrointestinal Cancer Symposium.
Read More
Clinical Trial Scenarios Help to Appropriately Include Patients With Brain Metastases
January 23rd 2018Clinical trials designed to evaluate the use of anti-cancer drugs for the treatment of cancer typically exclude patients whose disease has spread to the brain or CNS for a number of reasons, including the misperception that they are poor clinical trial candidates.
Read More
Beta Blockers May Lower Stress, Help Boost Immunotherapy Treatment Response
January 18th 2018A study, conducted at Penn State College of Medicine, demonstrated that patients with melanoma who received immunotherapy while also taking a specific type of beta blocker lived longer than those who received immunotherapy alone.
Read More
Despite Clinical Efficacy, Only Certain Myeloma Treatments Are Cost-Effective
January 17th 2018Over the past few years, the Food and Drug Administration (FDA) has approved a variety of triplet combinations for the treatment of patients with multiple myeloma. However, little is known which regimens have the best economic impact, without sacrificing clinical outcomes that is.
Read More
Drug Shows Promise in Reducing Oral Mucositis in Patients With Head and Neck Cancer
January 11th 2018Oral mucositis causes pain, the inability to eat which can also lead to nutritional problems, and an increased risk for infection as a result of open sores. In turn, these symptoms can lead to reduced quality of life, chemotherapy or radiation dose-limiting, and increased treatment costs from antibiotics or narcotics or additional or longer hospital stays.
Read More
Exercise Before and After Lymphoma Diagnosis May Improve Survival
January 10th 2018The researchers noted that physical activity plays an important role in lymphoma survivorship, and the data may provide rationale for a clinical trial to evaluate exercise intervention in this patient population.
Read More
Patients With Brain Tumors Face Late Hospice Enrollment and Utilization
January 4th 2018Adequate end-of-life care derives a variety of benefits for both patients and their families, including less invasive and ineffective intervention and less financial burden, said study author Justin Jordan, M.D., MPH, clinical director of the Pappas Center for Neuro-Oncology at Massachusetts General Hospital (MGH) Cancer Center.
Read More
Timely Hospice Use Increases Among Patients with Myeloma
January 1st 2018Researchers found a significant trend toward increased hospice use by people who have multiple myeloma between 2010 and 2013, which indicates that they are receiving more effective pain management toward the end of their lives.
Read More
Thyroid Cancer Survivors Diagnosed Before 40 At Higher Risk For Aging-Related Disease
December 31st 2017Patients diagnosed with thyroid cancer before the age of 40 appear to be at the highest risk for age-related diseases, including heart disease and diabetes, compared with their age-matched counterparts.
Read More
3-D Simulation Helps Patients See Radiation Therapy Plan Firsthand
December 29th 2017The Virtual Environment Radiotherapy Training (VERT™) system, originally designed to teach medical students and physicians about administering radiation therapy, is being used to explain to people who have prostate cancer what their treatment will look like.
Read More
Foundation Continues Legacy to 'Never Give Up'
December 29th 2017The V Foundation for Cancer Research was founded by ESPN and legendary basketball coach Jim Valvano with one goal in mind: to achieve victory over cancer. Since its start in 1993, the V Foundation has awarded over $200 million in cancer research grants nationwide and has grown to become one of the premier supporters of cutting-edge cancer research funds.
Read More
Identifying Safe Windows for Melanoma Surgery Improves Survival
December 27th 2017A study published in the Journal of the American Academy of Dermatology evaluated the impact of time between melanoma diagnosis and surgery on the survival of people with stage 1 to stage 3 cutaneous melanoma.
Read More
Childhood Cancer Survivors at Increased Risk for High Blood Pressure
December 23rd 2017Approximately 420,000 Americans are adult survivors of childhood cancer, and these individuals may be twice as likely to have high blood pressure, also known as hypertension, according to researchers at St. Jude Children’s Research Hospital.
Read More